Opportunities in Infectious Disease Diagnostics Market

CITY, Country, 2019-Oct-11 — /EPR Network/ —

The global infectious disease diagnostics market is valued at USD 14,725.7 million in 2017 and is expected to grow at CAGR of 5.6% to USD 19,351.3 million by 2022 during the forecast period. The infectious disease diagnostics market is mainly driven by factors such as the increasing global prevalence of infectious diseases, the shift in focus from centralized laboratories to decentralized point-of-care testing, and growth in funding for research on infectious disease diagnostics. Advances in genomics and proteomics, growing awareness about personalized medicine, and growth opportunities in emerging markets are expected to present opportunities for players in the market. On the other hand, inadequate reimbursements and rising healthcare costs limiting the use of novel diagnostic techniques are expected to limit market growth during the forecast period.

Advances in genomics and proteomics

The Human Genome Project and advances in molecular and biomedical technologies have generated vast amounts of data, which have resulted in the development of a multitude of assays and technologies useful for the diagnosis and management of various infectious diseases. These new technologies, based on genomic techniques (such as PCR) and proteomics (such as microarray-based detection), help in the discovery of new bacteria and viruses. They also enable better surveillance and rapid diagnosis of infectious diseases.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=116764589

These advanced technologies developed through the combined efforts of pharmaceutical research companies, the medical community, and government agencies can help combat the threat posed by influenza infections in the coming years.

Growth opportunities in emerging markets

Developing economies such as India, China, South Korea, Brazil, Turkey, Russia, and South Africa are expected to offer potential growth opportunities for the major players operating in the infectious disease diagnostics market. This can be attributed to the high disease prevalence, large patient population, improving healthcare infrastructure, increasing disposable income, and growing medical tourism in these countries.

The incidence of chronic diseases has increased significantly in these countries. According to UNAIDS Data 2017, ~1.8 million new cases of HIV infections were reported in Asia Pacific, Latin America, the Caribbean, and Africa. According to the WHO Malaria Report 2016, there were 212 million new cases of malaria worldwide in 2015 (range 148–304 million) with the African region accounting for most of the global cases of malaria (90%), followed by Southeast Asia (7%). The huge untapped market in these countries can be targeted with cost-effective clinical laboratory procedures, along with conventional infectious disease diagnosis.

These markets are expected to witness moderate growth in the forecast period, primarily due to the increasing spending power, growing healthcare awareness, and implementation of favorable government initiatives. For instance, China is the world’s second-largest investor in R&D with an expected spending of USD 396.3 billion in 2016.

Moreover, as the markets in the US and Europe are reaching maturity, a majority of players are expected to shift their focus to emerging markets. Heavy investments in healthcare and life science research in emerging markets will also play an important role in upgrading the laboratory infrastructure in these countries. This, in turn, is expected to increase the installation base of diagnostic systems in laboratories in these countries.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=116764589

Browse Related Reports:

In Vitro Diagnostics Market by Product (Instruments, Reagents), Technology (Immunoassay, Clinical Chemistry, Molecular Diagnostics, Hematology, Urinalysis), Application (Diabetes, Oncology, Cardiology, Nephrology) – Forecast to 2023

Esoteric Testing Market by Type (Infectious Disease, Endocrinology, Oncology, Toxicology, Immunology, Neurology, Genetic Testing), Lab Type (Independent Labs, Hospital Laboratories), Technology (Mass Spectrometry, CLIA, ELISA, PCR) – Global Forecast to 2023

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledge Store” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: +1-888-600-6441

Email: sales@marketsandmarkets.com

Visit Our Website: https://www.marketsandmarkets.com

Matched content

Editor’s pick